ΕΛ

Keratea

Plants featuring:

  • High capacity & flexibility in the management of pharmaceutical forms.
  • Technological superiority and differentiation.
  • Potential to access new markets worldwide.
Keratea
Keratea
Keratea
Keratea
Keratea
Keratea
NEW Plant I in Keratea
  • Total area: 15,000 m²
  • Manufacturing of 35 million pMDIs
  • Manufacturing of 36 million tablets - capsules
  • 300 employees
  • Activity focused on the production and development of inhalation products (for asthma and chronic obstructive pulmonary disease) and solid forms (cardiological, antihypertensives, respiratory and central nervous system diseases, antibiotics).
  • - 2 manufacturing units which, when operating at full capacity (3 shifts/day), can produce 71,000,000 packages annually.

UNIQUE in Greece and one of 4 in Europe.

NEW Plant II in Keratea (2026 - 2027)
  • Total area: 8,000 m²
  • Manufacturing of 30 million tablets
  • >200 employees
  • Activity focusing on the production and development of medicines in tablet form (cardiological, antihypertensives, central nervous system diseases, antibiotics).
  • 3 manufacturing units

Through the manufacturing capacity of the Keratea plant, ELPEN can serve more than 8,000,000 patients in Greece & abroad.

ELPEN - The leading greek pharmaceutical company
Search